The Enduring Success of Hybridoma-based Antibody Development

Since its original development in 1975, hybridoma technology encourages researchers all over the world to share their antibodies with one another, unlocking a vast amount of potential for biological research.

Due to their high selectivity, monoclonal antibodies (mAbs) are used in a wide range of disciplines, including research, diagnostics and therapeutic applications. Despite the advancement of modern antibody generation technologies, hybridoma-based antibody production continues to be a leading approach for mAb discovery and development.

Download these whitepapers to explore:

• The key benefits of using hybridoma-based antibody development
• Perceived misconceptions relating to hybridoma technology
• Alternative approaches that currently exist for mAb generation